Thursday, September 02, 2021 11:16:25 AM
https://www.ibtimes.com/sinovac-covid-19-vaccine-has-0-40-antibody-levels-compared-pfizers-1300-expert-3285248
AND:
[Global Times (The Chinese Government's propaganda media, for internal use only): "In the group of participants who received the 3µg vaccine (of Sinovac's Coronavac), which is approved for emergency use, the geometric mean titer (GMT) of serum neutralizing antibodies increased to 305 on day seven after the third dose, an approximately seven-fold increase compared to the levels at day 28 after the second dose."
? (!) Compared with INO-4800 Phase 2 preprint data: INO-4800 second dose GMT = 2,210.
So INO-4800 second dose produces 7 times more neutralizing antibodies than Sinovac third dose.] By CAD
A study in China found that SinoVac and SinoPharm were 70% effective in preventing COVID-19 infection
A preprint study in Brazil found that SinoVac was only 54% effective in preventing coronavirus infection
Singapore had previously refused to count SinoVac jabs in the country's tally of vaccinations
The China-made COVID-19 vaccine, SinoVac, has been found to produce significantly lower levels of antibodies compared to the vaccine developed by Pfizer-BioNTech, prompting residents in Singapore to get booster shots.
Antibody levels in people who have received two doses of the Pfizer vaccine were normally between 1,300 and 2,000 international units per milliliter. However, the numbers are much lower in individuals who received two shots of the SinoVac vaccine.
“For Sinovac, it is zero to 40. We have a few with 200 to 300,” Dr. Leong Hoe Nam, an infectious diseases specialist at Rophi Clinic in Singapore, told South China Morning Post.
Dr. Leong noted that the lower antibody levels in SinoVac recipients have prompted an increasing number of individuals to get Pfizer as a booster shot.
“They took the Sinovac shots, did the blood test and saw low antibody levels, then opted for Pfizer as the third dose,” he added.
A study conducted by researchers in China found that the SinoVac and SinoPharm vaccines had a combined efficacy of 70% in preventing an infection caused by the more contagious Delta variant in the city of Guangzhou. The study, which has yet to be peer reviewed, also noted that the shots were 100% effective in preventing severe infections and deaths.
However, a Brazilian preprint study comparing SinoVac to the AstraZeneca COVID-19 vaccine found that recipients of the Chinese-made vaccine had lower protection levels against the virus.
SinoVac recipients were 54% less likely to contract COVID-19 and 74% less likely to die of the virus compared to the unvaccinated. The efficacy waned in the older population, reducing the risk of death by only 35% in people over the age of 80. In comparison, AstraZeneca reduced the risk of infection by 70% and the risk of death by 90%.
The Singaporean government had previously excluded people who received the SinoVac shots from the country’s total count of vaccinations. Health Minister Ong Ye Kung cited inadequate efficacy data as the reason for the move.
"We don't really have a medical or scientific basis or have the data now to establish how effective SinoVac is in terms of infection and severe illnesses on Delta," Ong said during a July media briefing, according to Reuters.
Singapore’s Ministry of Health later announced it will consider people who received vaccine shots included in the World Health Organization’s emergency use list, such as SinoVac, Sinopharm and AstraZeneca, as fully vaccinated, in an effort to be more “inclusive.”
“What is important now is the difference between those who are vaccinated and not vaccinated and less so between different vaccines,” Ong said at a press conference in early August.
Despite this, the Singaporean government is still offering third doses of vaccines to residents who had taken the SinoVac jab as part of a “heterologous vaccination strategy.”
"We have not stopped them although data is still lacking considering what the effectiveness is of this strategy using two different vaccines – we call this a heterologous vaccination strategy," Director of Medical Services Kenneth Mak said during a virtual doorstop interview.
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM